Inovio Pharmaceuticals
Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).
| Company type | Public |
|---|---|
Traded as | Nasdaq: INO |
| Industry | Biotechnology |
| Founded | 1999 |
| Headquarters | Plymouth Meeting, Pennsylvania |
Key people | Jacqueline Shea, Ph.D. (President and CEO) |
| Products | DNA-based Medicines and Vaccines |
| Revenue | $7 Million(2020) |
Number of employees | 262 |
| Website | inovio.com |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.